{"entity":{"id":"vididencel","kind":"drug","name":"Vididencel","aka":["DCP-001","DCOne"],"tldr":"Vididencel is an experimental allogeneic cell-based active immunotherapy, given intradermally from Mendus, in phase 2 trials for acute myeloid leukaemia, chronic myeloid leukaemia and high-risk ovarian cancer.","summary":"Vididencel (DCP-001, DCOne) is an allogeneic cell-based active immunotherapy (dendritic cell vaccine from a leukaemia cell line), given intradermally from Mendus. An off-the-shelf active immunotherapy made from a proprietary leukaemia cell line, designed to trigger immune responses against cancer cells left after standard treatment. Its furthest stage is phase 2, for acute myeloid leukaemia (maintenance), chronic myeloid leukaemia (treatment-free remission) and high-risk ovarian cancer. ClinicalTrials.gov registers it in 4 studies linked below. AML phase 2 ADVANCE II (NCT03697707, registry status unknown); CML phase 1 NCT07651878 recruiting; ovarian cancer phase 1 NCT04739527 completed. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Mendus: mendus.com","url":"https://www.mendus.com/what-we-do/"},{"label":"Mendus: mendus.com","url":"https://www.mendus.com/what-we-do/"},{"label":"Mendus: mendus.com","url":"https://www.mendus.com/what-we-do/"},{"label":"Mendus: stockanalysis.com","url":"https://stockanalysis.com/quote/sto/IMMU/company/"},{"label":"ClinicalTrials.gov: trials of DCP-001","url":"https://clinicaltrials.gov/search?intr=DCP-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03697707","nct01373515","nct04739527","nct07651878"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DCP-001","modality":"Allogeneic cell-based active immunotherapy (dendritic cell vaccine from a leukaemia cell line), given intradermally","mechanism":"An off-the-shelf active immunotherapy made from a proprietary leukaemia cell line, designed to trigger immune responses against cancer cells left after standard treatment.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vididencel/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}],"trial":[{"id":"nct03697707","kind":"trial","name":"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia","route":"/trials/nct03697707/"},{"id":"nct01373515","kind":"trial","name":"Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia","route":"/trials/nct01373515/"},{"id":"nct04739527","kind":"trial","name":"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","route":"/trials/nct04739527/"},{"id":"nct07651878","kind":"trial","name":"Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment","route":"/trials/nct07651878/"}]}}